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Abstract 87 
Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2000-88 
3000, is characterized by a highly variable clinical presentation. To date, only two clinically 89 
relevant intragenic genotype-phenotype correlations have been reported for NF1 missense 90 
mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants 91 
predispose to a distinct mild NF1 phenotype with neither externally visible cutaneous/plexiform 92 
neurofibromas nor other tumors. Here, we report 162 individuals (129 unrelated probands and 33 93 
affected relatives) heterozygous for a constitutional missense mutation affecting one of five 94 
neighboring NF1 codons Leu844, Cys845, Ala846, Leu847 and Gly848, located in the Cysteine-95 
Serine-Rich Domain (CSRD). Collectively, these recurrent missense mutations affect ~0.8% of 96 
unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham (UAB) 97 
cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were 98 
more prevalent in these individuals compared with classic NF1 cohorts (both p<0.0001). Nearly 99 
half of the individuals had symptomatic or asymptomatic optic pathway gliomas and/or skeletal 100 
abnormalities. Additionally, variants in this region seem to confer a high predisposition to 101 
develop malignancies compared with the general NF1 population (p=0.0061). Our results 102 
demonstrate that these NF1 missense mutations, although located outside the GAP-related 103 
domain, may be an important risk factor for a severe presentation. A genotype-phenotype 104 
correlation at the NF1 region 844-848 exists and will be valuable in the management and genetic 105 
counseling of a significant number of individuals.  106 
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Introduction 107 
Neurofibromatosis type 1 (NF1 [MIM: 162200]), one of the most common genetic disorders with 108 
a birth incidence of 1 in 2000-3000 [1-3], is characterized by a highly variable inter- and 109 
intrafamilial expressivity [4]. It is caused by loss-of-function genetic variants in NF1 (MIM: 110 
613113), located on chromosome 17q11.2. NF1 encodes neurofibromin, a GTPase activating 111 
protein (GAP) that down-regulates the RAS signal transduction pathway through its GAP-related 112 
domain (GRD) [5, 6]. The most common first signs of NF1 are multiple café-au-lait macules 113 
(CALMs) in >95% of infants and skinfold freckling in >80% of children by the age of 7 years 114 
[7]. Other clinical features observed in >90% of adults with NF1 are iris Lisch nodules and 115 
cutaneous neurofibromas [8]. Individuals with a more severe phenotype present with plexiform 116 
and/or spinal neurofibromas, symptomatic optic pathway gliomas (OPGs) as well as specific 117 
osseous lesions, such as sphenoid wing or tibial dysplasia. Approximately 50% of NF1 cases 118 
have de novo mutations, while the remaining individuals inherit the disorder from an affected 119 
parent [4]. According to the National Institutes of Health (NIH) diagnostic criteria at least two of 120 
the aforementioned features are required to classify a person as having the clinical diagnosis of 121 
NF1 [9].  122 
Due to the variability in clinical presentation, age-dependency of most manifestations, the timing 123 
and number of second hits in specific cells, and the wide NF1 allelic heterogeneity, identification 124 
of specific genotype-phenotype correlations is extremely challenging. To date, over 2800 125 
different germline NF1 pathogenic variants have been identified in the University of Alabama at 126 
Birmingham (UAB) cohort with only 31 unique pathogenic variants present in ≥0.5% of all 127 
unrelated individuals (L.M.M, unpublished data). Moreover, a mild NF1 phenotype, including 128 
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only CALMs and skinfold freckles, overlaps with Legius syndrome (MIM: 611431), caused by 129 
mutations in SPRED1 (MIM: 609291) [10, 11].  130 
So far, only three clinically significant genotype-phenotype correlations have been reported. 131 
First, individuals with a constitutional NF1 microdeletion usually show a more severe phenotype 132 
compared to the general NF1 population. The NF1 microdeletion syndrome (MIM: 613675) is 133 
typically characterized by a large number of neurofibromas at a young age, dysmorphic facial 134 
features (hypertelorism, downslanted palpebral fissures, broad nasal bridge, low set ears, 135 
micrognathia, coarse face, facial asymmetry) and developmental delay and/or intellectual 136 
disability. Individuals may present with cardiac defects as well as growth and skeletal 137 
abnormalities. NF1-microdeletions have been associated with an increased lifetime risk for 138 
malignant peripheral nerve sheath tumors (MPNSTs). The constitutional co-deletion of SUZ12 139 
(MIM: 606245) within the common NF1-microdeletion region is thought to be a risk factor for 140 
the malignant neoplasms [12]. Second, individuals with a specific single amino acid NF1 141 
deletion (c.2970_2972del; p.Met992del) present with a milder phenotype. These individuals 142 
have multiple CALMs with/without freckles, but no externally visible cutaneous or plexiform 143 
neurofibromas [13]. A third genotype-phenotype correlation involving NF1 missense mutations 144 
affecting arginine at position 1809 is also associated with a distinct presentation [14, 15], 145 
including developmental delay and/or learning disabilities, pulmonic stenosis and Noonan-like 146 
features, but no external plexiform neurofibromas or symptomatic OPGs. Both of these affected 147 
amino acids reside outside the GRD domain. 148 
Another distinct form of NF1 is familial spinal neurofibromatosis (FSNF [MIM: 162210]) 149 
originally described by Pulst et al. (1991) [16] in six affected members from two unrelated 150 
families. It is characterized by bilateral and histologically proven neurofibromas of all spinal 151 
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dorsal roots with a paucity or absolute lack of cutaneous manifestations [17, 18]. So far, only 152 
~100 individuals (both familial and sporadic) have been reported with this form [18]. It has been 153 
suggested that individuals with the severe subtype of FSNF more frequently carry an NF1 154 
missense or splicing mutation [19-21]. Of particular interest are two families: a two-generation 155 
family with three first-degree relatives reported by Pascual-Castroviejo et al. (2007) [22] and a 156 
three-generation family with three first-degree relatives reported by Burkitt-Wright et al. (2013) 157 
[17]. Specific NF1 missense mutations c.2542G>C (p.Gly848Arg) and c.2543G>A 158 
(p.Gly848Glu), located in the Cysteine-Serine-Rich Domain (CSRD), were present in all 159 
individuals affected by multiple spinal dorsal root neurofibromas. Despite the evidence that 160 
c.2542G>C (p.Gly848Arg) is a clearly pathogenic mutation, two recent studies using mouse 161 
models did not recapitulate the phenotype identified in humans [23, 24]. Genetically engineered 162 
mice with c.2542G>C (p.Gly848Arg) mutation developed neither OPGs [24] nor plexiform 163 
neurofibromas [23], demonstrating phenotypic divergence between NF1 individuals and mice. 164 
In this study, we report a cohort of 129 unrelated probands and 33 affected relatives 165 
heterozygous for a constitutional missense mutation affecting one of five neighboring NF1 166 
codons Leu844, Cys845, Ala846, Leu847 and Gly848. These individuals have a high prevalence 167 
of a severe phenotype, including plexiform and symptomatic spinal neurofibromas, symptomatic 168 
optic pathway gliomas, other malignant neoplasms, as well as bone abnormalities. The current 169 
findings clearly demonstrate that missense mutations outside the GRD are not solely associated 170 
with a mild phenotype.   171 
 172 
Materials and methods 173 
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Individuals and phenotypic data 174 
A total of 162 individuals heterozygous for a missense mutation affecting one of five 175 
neighboring NF1 codons Leu844, Cys845, Ala846, Leu847 and Gly848 were included in the 176 
study. Blood samples from seventy-eight individuals (67 probands and 11 relatives) were 177 
originally sent to the UAB Medical Genomics Laboratory for molecular NF1 genetic testing to 178 
establish or confirm the diagnosis for NF1. This initial study was expanded to include an 179 
additional eighty-four individuals (62 probands and 22 relatives), molecularly diagnosed in 180 
collaborating institutions (as detailed in Table S1). 181 
All individuals included in this study were clinically assessed using the standardized phenotypic 182 
checklist form as previously reported [15] (Figure S1). The clinical data were collected at the 183 
time of mutation analysis and re-verified for accuracy by referring physicians co-authoring this 184 
paper at the time of this study. Additionally, referring physicians updated the phenotypic data at 185 
the time of this genotype-phenotype study, when available, i.e. when the individual had been 186 
seen and followed at their institution after genetic testing results were reported. The phenotypic 187 
data and age provided correspond to the latest clinical evaluation. The phenotypic checklist form 188 
consists of two parts: i/ general information including gender, date of birth, ethnicity, height, 189 
head circumference (HC), weight, fulfillment of the NIH diagnostic criteria and mode of 190 
inheritance and ii/ NF1 signs and symptoms, including CALMs, skinfold freckling, Lisch 191 
nodules, cutaneous and subcutaneous, plexiform and spinal neurofibromas, OPGs and other 192 
neoplasms, skeletal and cardiac abnormalities, development and education levels, 193 
presence/absence of Noonan features and segmental phenotype.  194 
Fifteen major clinical features of NF1 were selected for the genotype-phenotype correlation 195 
study (Tables 1-3). Individuals with missing data for a particular sign and/or symptom were 196 
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classified as “unknown” or “not specified” and consequently excluded from that part of the 197 
genotype-phenotype analysis. Most features were identified by physical examination; 198 
ophthalmologic examination for Lisch nodules and imaging to detect asymptomatic OPGs and 199 
spinal neurofibromas was not performed in most individuals. Brain and spine/whole body MRI 200 
was done mainly in individuals with signs and/or symptoms indicative of OPGs or internal/spinal 201 
neurofibromas; however, depending on institutional policies, some individuals were screened by 202 
MRI despite the absence of symptoms. Noonan phenotype was diagnosed if at least two of the 203 
following features were observed: short stature, hypertelorism, low set ears, webbed neck, ptosis, 204 
midface hypoplasia or pulmonic stenosis. To evaluate short stature and macrocephaly, the World 205 
Health Organization (WHO) and the Center for Disease Control (CDC) growth charts and the 206 
Gerhard Nellhaus’ curve [25] were used as previously described [15]. Short stature and 207 
macrocephaly were defined as height below or equal to the 3rd percentile (PC≤3) and as head 208 
circumference equal or above the 98th percentile (PC≥98), respectively. For cognitive 209 
impairment/learning disabilities, individuals with attention deficit disorder (ADD) and/or 210 
attention deficit hyperactivity disorder (ADHD) but normal development were classified as 211 
normal.  212 
To establish a genotype-phenotype association we used the same approach as previously 213 
described [15]. We compared the phenotypes of individuals with missense mutations affecting 214 
codons 844-848 with the cohort of 169 individuals with missense mutations affecting p.Arg1809 215 
[14, 15, 26-28], 47 individuals heterozygous for c.2970_2972del (p.Met992del) mutations [13] 216 
and previously described large scale NF1 individual cohorts with “classic” NF1 [8, 29-41]. 217 
This study was approved by the Institutional Review Boards of all participating institutions 218 
offering clinical genetic testing.  219 
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 220 
Molecular analysis 221 
In the Medical Genomics Laboratory at UAB comprehensive NF1 mutation screening using an 222 
RNA-based approach complemented by DNA-dosage analysis was performed as previously 223 
described [42, 43]. The status of the specific familial mutation in relatives was ascertained by 224 
bidirectional Sanger sequencing (ABI PRISM 3730, Life Technologies). 225 
The nomenclature of the mutations is based on NF1 mRNA sequence NM_000267.3 according 226 
to the recommendations of the Human Genome Variation Society (HGVS). For exon numbering 227 
we used the NCBI numbering, followed by the historical numbering in square brackets originally 228 
developed by the NF1 community [43]. 229 
 230 
In silico prediction of effect of missense mutations 231 
Seven software programs were used to predict the effects of missense variants: two online in 232 
silico prediction tools (CADD v1.3 and PolyPhen-2) and five complementary tools (Grantham 233 
Difference, SIFT v4.0.3, SpliceSiteFinder-like, MaxEntScan, NNSplice v0.9 and Human 234 
Splicing Finder v2.4.1) embedded in Alamut visual software v2.9.0 (Interactive Biosoftware). 235 
The presence or absence of the variants was checked in population databases, including the 236 
Genome Aggregation Database (gnomAD), 1000 Genomes and the Exome Variant Server (EVS) 237 
as well as in disease databases: the Leiden Open Variation Database (LOVD), ClinVar and the 238 
Human Gene Mutation Database (HGMD) (last accessed May 2017). Evolutionary conservation 239 
for human neurofibromin NP_000258.1 residues 804-950 was evaluated using Clustal software 240 
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v2.0.12. The palindromic sequences and quadruplex forming G-Rich sequences (QGRS) were 241 
identified by Palindrome search and QGRS Mapper, respectively.  242 
Interpretation of variant pathogenicity was performed based on the American College of Medical 243 
Genetics (ACMG) recommendations [44].   244 
 245 
Statistical analysis 246 
For univariate analysis, two-tailed Fisher’s exact test was used to compare categorical variables 247 
with a p-value <0.05 considered as statistically significant. The resulting p-values were adjusted 248 
for multiple comparisons using Benjamini-Hochberg (B-H) procedure with false discovery rates 249 
(FDRs) of 0.05 and 0.01. The 95% confidence interval (CI) was also calculated when 250 
appropriate. All statistical analyses were performed with GraphPad and VassarStats softwares.  251 
 252 
Results 253 
Description of missense mutations affecting codons 844-848 254 
Exon 21 [16] is the largest NF1 exon (441 nucleotides), and in it we identified, besides the 255 
missense variants affecting the codons 844-848, a total of 19 different missense variants in 35 256 
unrelated individuals from the UAB cohort. Fourteen of these alterations were classified as 257 
variants of uncertain significance (8/19) or likely benign (6/19) and reported 1-3 times in the 258 
UAB cohort (Figure S2). Only five variants were classified as pathogenic (4/19) or likely 259 
pathogenic (1/19) according to the current recommendations [44]. Region 844-848 in exon 21 260 
[16] stood out due to its high frequency of variants compared with the neighboring codons, 261 
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indicating functional importance (Figures S2 and S3). A similar distribution and spectrum of 262 
missense alterations in the NF1 exon 21 [16] was observed in the publicly available databases 263 
(ClinVar, LOVD and HGMD). Besides a clear cluster of recurrent variants in codons 844-848, 264 
other alterations spread over the entire exon 21 [16] were mostly classified as variants of 265 
uncertain significance and reported 1-2 times in these databases (Figure S2). The frequency of 266 
this cluster of variants in AA844-848 is ~0.8% (67/8400) in unrelated NF1 mutation-positive 267 
individuals from the UAB cohort, second only to the p.Arg1809 (~1.2%), and therefore 268 
represents a significant hotspot for missense mutations within NF1.  269 
In the 129 unrelated individuals reported here, we identified 12 different NF1 missense 270 
alterations affecting one of five neighboring codons in exon 21 [16] (Table 1 and Figure 1). 271 
Within the group of individuals with p.Gly848Arg, two different substitutions were observed: 272 
c.2542G>A (6/14) and c.2542G>C (8/14). Detailed characteristics of the identified missense 273 
mutations are shown in Tables S2 - S4 and Figure 1. All variants identified in this study with 274 
confirmed origin of the variant were submitted to the LOVD and ClinVar databases. Based on 275 
the data accumulated in this report (Table S1 and Table S2), these variants can all be classified as 276 
pathogenic (Table S4) according to current recommendations [44]. 277 
Among the aforementioned variants, 8/12 were present in the LOVD database with 5/8 classified 278 
as pathogenic [c.2533T>C (p.Cys845Arg), c.2536G>C (p.Ala846Pro), c.2537C>A 279 
(p.Ala846Asp), c.2540T>C (p.Leu847Pro), c.2543G>A (p.Gly848Glu)] and 3/8 as variants of 280 
uncertain significance [c.2534G>A (p.Cys845Tyr), c.2540T>G (p.Leu847Arg), c.2542G>C 281 
(p.Gly848Arg)]. Eight of the 12 were present in ClinVar, including 3/8 classified as pathogenic 282 
[c.2531T>G (p.Leu844Arg), c.2540T>C (p.Leu847Pro), c.2542G>C (p.Gly848Arg)], 1/8 as 283 
likely pathogenic [c.2534G>A (p.Cys845Tyr)], 1/8 as a variant of uncertain significance 284 
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[c.2533T>C (p.Cys845Arg)], and 3/5 with no significance provided [c.2530C>T (p.Leu844Phe), 285 
c.2531T>C (p.Leu844Pro), c.2543G>A (p.Gly848Glu)] (Table S2 and Table S3). One individual 286 
(UAB-R4444) with c.2531T>A (p.Leu844His) carried another novel alteration c.2524G>A; 287 
assuming both variants reside in cis, this alteration should be described as 288 
c.2524_2531delinsAGCTTCCA (p.Gly842_Leu844delinsSerPheHis). None of these variants, 289 
except for c.2531T>G (p.Leu844Arg), has been reported in 129,639 unrelated controls of the 290 
gnomAD and EVS databases or in the 1000 Genomes Project; c.2531T>G (p.Leu844Arg) was 291 
reported once in Latino (the variant’s frequency in all populations is 0.00041%). Based on in 292 
silico analysis all alterations are predicted to be deleterious (SIFT) and probably or possibly 293 
damaging (PolyPhen-2). Additionally, CADD classified all variants as more likely to have 294 
deleterious effects (range: 22.6 to 31). In contrast to results of in silico analysis, suggesting a 295 
possible effect of two identified alterations (c.2542G>A and c.2543G>A) on splicing through 296 
creation of a novel exonic splice acceptor sequence, transcript analysis and sequencing showed a 297 
minor effect on splicing only for c.2542G>A in three individuals (UAB-R9493, UAB-R1474 and 298 
UAB-R0008), i.e. low levels of r.2410_2543del. The other individuals with c.2542G>A screened 299 
with an RNA-based approach (UAB-R3513 and UAB-R4476) in whom no missplicing was 300 
observed, also carried the nearby benign variant c.2544G>A (p.Gly848=) (rs17883704) with 301 
both variants proven to reside in cis through next-generation sequencing. As missplicing was 302 
only observed in individuals carrying c.2542G>A in the absence of rs17883704 (Figure S4), 303 
rs17883704 is hypothesized to have a modifying effect. All missense mutations, except for 304 
c.2536G>C (p.Ala846Pro) were proven to be de novo in at least one proband; a total of 26 305 
probands with unaffected parents were proven to have a de novo mutation, but formal 306 
confirmation of paternity/maternity by identity testing was only pursued for individuals tested in 307 
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the Netherlands (ROT-R02233, ROT-R22853 and ROT-R17435). Additionally, 7/12 missense 308 
mutations [c.2530C>T (p.Leu844Phe), c.2533T>C (p.Cys845Arg), c.2536G>C (p.Ala846Pro), 309 
c.2537C>A (p.Ala846Asp), c.2540T>C (p.Leu847Pro), c.2542G>C (p.Gly848Arg) and 310 
c.2543G>A (p.Gly848Glu)] segregated with the phenotype (at least one individual per family) in 311 
23 affected first-degree relatives from 15 families (Table S1, Table S2 and Figure S5). Finally, 312 
all missense mutations affecting amino acids 844-848 are located in a highly conserved region of 313 
the CSRD (amino acids 543-909; Figure S6). Besides cysteine at position 845 that is conserved 314 
up to Zebrafish, all remaining amino acids are evolutionarily conserved up to Drosophila 315 
melanogaster (Ala846 and Gly848) and even to yeast IRA1 and/or IRA2 (Leu844 and Leu847). 316 
In chimpanzee, rat and mouse all amino acids from 775 to 856 are fully evolutionarily 317 
conserved. None of these variants has been functionally characterized.  318 
 319 
Demographic and clinical characterization of the studied cohort 320 
A total of 162 individuals from 129 unrelated families were enrolled in the study, including 321 
37/129 (28.7%) familial and 89/129 (69%) sporadic cases; 3/129 (2.3%) individuals had an 322 
unknown family history (ROT-R13734, ROT-R89874 and CAR-R8012M6). Detailed 323 
demographic and clinical descriptions of the individuals included in the study are shown in Table 324 
1, Table S1 and Figure S5.  325 
The complete phenotypic checklist forms were collected from 151/162 individuals (93.2%). Of 326 
these, 125/151 (82.8%) fulfilled the NIH diagnostic criteria and 118/151 (78.2%) fulfilled the 327 
NIH diagnostic criteria if family history was excluded as a criterion. Among 26/151 individuals 328 
who did not fulfill the NIH diagnostic criteria (with 20/26 being ≤8 years), multiple CALMs-329 
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only (>5) were present in 16/26, <6 CALMs-only were present in 8/26 and 2/26 did not have any 330 
pigmentary manifestations, but had externally visible plexiform neurofibromas (UAB-R9135 and 331 
UG-R5831) (Table S5). CALMs-only (<6) were observed mostly in individuals with a missense 332 
mutation at codon 848 [6/8 with c.2542G>C (p.Gly848Arg), 1/8 with c.2543G>A (p.Gly848Glu) 333 
and 1/8 with c.2534G>A (p.Cys845Tyr)]. 334 
Among 102 individuals ≥9 years, more than 5 CALMs and skinfold freckling were present in 335 
79.8% (79/99) and 80% (76/95), respectively (Table 1). Both clinical features were found in 336 
71.6% (68/95) of cases. Out of 20 individuals ≥9 years with only few or absolute lack of CALMs 337 
(Table S1), 11 cases fulfilled the NIH diagnostic criteria based on presence of other clinical 338 
signs, such as skinfold freckles, Lisch nodules, neurofibromas and/or osseous lesions (UG-339 
R0781, UAB-R3618-M, MIL-R192/982-F, UAB-R4476, MIL-R999/399, MIL-R999/399-M, 340 
ROT-R95424, UG-R923-S, UAB-R3237, MAN-R95417G, MAN-R95417G-C). Among these 341 
individuals, 8/11 (72.7%) carried a missense mutation at codon 848. Lisch nodules were reported 342 
less frequently (42/98 all ages, but in 34/60 ≥9 years).  343 
Cutaneous and subcutaneous neurofibromas were found in 68.1% (47/69 ≥19 years) and 50.8% 344 
(33/65 ≥19 years) of the cases, respectively. Thirty adults had both types of tumors (30/64 ≥19 345 
years, 46.9%). Ten individuals ≥17 years had >100 cutaneous and/or subcutaneous nodules, 346 
including a 47-year-old man previously reported [45] with >1,400 neurofibromas (individual 347 
counts of externally visible neurofibromas; BRA-R38) and a 17-year-old young woman (ROT-348 
R1CMUL) with >500 cutaneous neurofibromas, >100 subcutaneous neurofibromas and >100 349 
intradermal neurofibromas. Nine out of ten individuals with a very high number of 350 
neurofibromas carried a missense mutation at codon 847: c.2540T>G (p.Leu847Arg) [2/9] or 351 
c.2540T>C (p.Leu847Pro) [7/9, including two individuals with metastasized MPNSTs]. In 16 352 
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cases with “several” neurofibromas a more precise estimated number was not reported. Eight 353 
individuals (UAB-R5776, UAB-R3618, UAB-R4624, UAB-R7447, UAB-R1002; UAB-R1037-354 
M, UAB-R3237, PAD-R500-C1) were reported to have a single cutaneous or subcutaneous 355 
nodule (none histopathologically confirmed); these individuals were considered as “negative for 356 
the criterion of neurofibromas” as ≥2 cutaneous/subcutaneous neurofibromas are required 357 
according to the NIH clinical criteria. 358 
Forty-five percent of the individuals ≥9 years had known plexiform neurofibromas (41/92 ≥9 359 
years; 47/143 all ages), including externally visible (n=36) and internal (n=5) tumors. For six 360 
cases, the information was not provided whether plexiform neurofibromas were identified 361 
clinically or by MRI. Among all individuals with plexiform neurofibromas, 31/47 presented with 362 
one plexiform tumor and 16/47 with ≥2 plexiform neurofibromas. Plexiform tumors were found 363 
in the head, face and neck area (35.7%, 25/70), limbs (34.3%, 24/70), trunk (17.1%, 12/70), back 364 
(n=3), abdomen (n=3), pelvis (n=2) and chest (n=1). 365 
Symptomatic spinal neurofibromas visible by MRI were found in 15.2% of individuals (12/79 ≥9 366 
years; 13/127 all ages). Forty asymptomatic individuals received MRI screening, leading to the 367 
identification of another seven cases with spinal tumors (Table S6). Approximately one-third of 368 
the individuals with spinal tumors (6/20) had fewer than 6 CALMs and no skinfold freckling, 369 
whereas in 60% (12/20) plexiform neurofibromas were observed (with 11/12 being externally 370 
visible).  371 
Symptomatic OPGs, confirmed by MRI imaging, were found in 11/104 of individuals older than 372 
5 years (10.6%), whereas asymptomatic OPGs were present in 16/52 additional individuals who 373 
underwent MRI examination (30.8% ≥5 years). In 19 of 27 symptomatic and asymptomatic 374 
OPGs, the detailed information about the tumor’s location was collected, involving optic nerves 375 
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(2 symptomatic OPGs and 7 asymptomatic OPGs), chiasm (1 symptomatic OPG and 1 376 
asymptomatic OPG) or both locations (6 symptomatic OPGs and 2 asymptomatic OPGs). Three 377 
children were diagnosed with a symptomatic OPG (PAD-R300) or asymptomatic OPGs (UAB-378 
R3714 and UAB-R3513) before age 4 years (Table S7). 379 
Skeletal abnormalities were frequently reported (48/144 all ages) and included scoliosis (27/144 380 
all ages, but 20/64 ≥19 years) and pectus anomalies (10/144 all ages: pectus carinatum 6/10 and 381 
excavatum 4/10). In addition, long bone dysplasia (n=4), pseudarthrosis (n=2), tibial dysplasia 382 
(n=1), bone cysts (n=2), sphenoid wing dysplasia (n=2), ulnar aplasia, likely representing the 383 
severe end of ulnar pseudarthrosis with bone resorption and absence of ulnar bone (n=1), dural 384 
ectasia (n=1), 4th lumbar vertebrae fragmentation (n=1), bowed long bones (n=1), clinodactyly 385 
(n=1), postaxial polydactyly (n=1) and cherubism (n=1) were observed in the studied group. 386 
Noonan syndrome features were observed in 10/134 (7.5%) individuals. One previously reported 387 
individual [46] (UAB-R624) with a family history of PTPN11-positive (MIM: 176876) Noonan 388 
syndrome (MIM: 163950) had a severe phenotype of pulmonic stenosis and aortic coarctation, 389 
dysmorphic features (high forehead, hypertelorism, downslanting palpebral fissures, short neck 390 
with a low posterior hair line), short stature, pectus carinatum, >5 CALMs, axillary and inguinal 391 
freckling, plexiform and cutaneous neurofibromas, symptomatic OPG with signs of 392 
hydrocephalus. Besides the familial PTPN11 c.1529A>G (p.Gln510Arg) inherited from the 393 
individual’s father, the NF1 missense mutation c.2531T>G (p.Leu844Arg) was found de novo in 394 
the proband (Figure S5). In other individuals with Noonan syndrome features (UAB-R2696, 395 
UAB-R5001, UAB-R3725 and UAB-R4676) no pathogenic or likely pathogenic variants in 396 
Noonan-related disorders genes (PTPN11 [MIM:176876], SPRED1 [MIM:609291], BRAF 397 
[MIM: 164757], CBL [MIM: 165360], HRAS [MIM: 190020], KRAS [MIM: 190070], MAP2K1 398 
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[MIM: 176872], MAP2K2 [MIM: 601263], NRAS [MIM: 164790], RAF1 [MIM: 164760], 399 
SHOC2 [MIM: 602775], SOS1 [MIM: 182530], RIT1 [MIM: 609591], RASA2 [MIM: 601589] 400 
and SOS2 [MIM: 601247]) were identified. Cardiovascular abnormalities observed in the studied 401 
group included hypertension (n=7, one related to renal artery stenosis), pulmonic stenosis (n=2), 402 
mitral valve stenosis, atrial septal defect, ventricular septal defect, Moyamoya disease, 403 
pericarditis carcinomatosa, mitral valve insufficiency, mild pulmonic insufficiency and 404 
hypertrophic cardiomyopathy (each observed in a single individual). Short stature (PC≤3) and 405 
macrocephaly (PC≥98) were found in 15/91 (16.5%) and 36/98 (36.7%), respectively. Of the 138 406 
cases with provided developmental data, 56 individuals had abnormal development presenting 407 
with at least one of the following forms of cognitive impairment and/or learning difficulties: 408 
learning disabilities (n=43), developmental delay (n=30), speech delay (n=8), ADD (n=8), 409 
ADHD (n=10), motor delay (n=5), autism spectrum (n=2), Asperger syndrome (n=1). Seven 410 
individuals had significant global developmental delay with/without speech delay, learning 411 
difficulties and/or AD(H)D, including one with a Full Scale Intelligence Quotient (FSIQ) score 412 
59. Additionally, three individuals were reported to have frequent migraine headaches, two had 413 
epilepsy and/or psychiatric problems. 414 
For 139/162 individuals, data on the presence or absence of tumors other than neurofibromas and 415 
OPGs was available. Thirteen of 139 (9.4%) individuals were diagnosed with malignant 416 
neoplasms (Table S8), including embryonal rhabdomyosarcoma (3/13), MPNST (7/13, including 417 
one woman with MPNST and BRCA1/2-negative breast cancer), colon cancer (1/13), medullary 418 
thyroid carcinoma (1/13) and juvenile myelomonocytic leukemia (JMML) (1/13). Individuals 419 
≥14 years old with c.2540T>C (p.Leu847Pro) had a higher number of malignant neoplasms 420 
compared to individuals carrying other missense mutations in the studied region (p=0.0448; 421 
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Table S9). Moreover, this mutation was present in most cases with MPNST (5/7), except for one 422 
each carrying c.2543G>A (p.Gly848Glu) or c.2530C>T (p.Leu844Phe). Four of seven 423 
individuals with MPNST died before age 30 years (Table S8). Hypothalamic glioma (n=1), 424 
lipoma (n=1), cerebral tumors (n=3), non-ossifying fibroma (n=2) and odontogenic fibroma 425 
(n=1) were also reported.  426 
The frequency of clinical features in individuals heterozygous for missense mutations affecting 427 
one of five neighboring codons 844-848 is presented in Table 2. A lower number of CALMs, 428 
freckling and cutaneous neurofibromas was observed in cases with missense mutations at codon 429 
848 (all p<0.0001; Table S9); however, these individuals had a higher prevalence of 430 
symptomatic spinal neurofibromas (p=0.0012; Table S9). 431 
Taken together, a severe phenotype, including at least one of the following features: plexiform 432 
and/or symptomatic spinal neurofibromas, symptomatic OPGs, malignant neoplasm or osseous 433 
lesions was observed in 75% of adult NF1 individuals (56/75 ≥19 years; Table 2).  434 
  435 
Comparison of clinical features observed in the studied cohort with individuals 436 
heterozygous for p.Arg1809 and p.Met992del mutations and cohort of individuals with 437 
“classic” NF1 phenotype 438 
Comparison of clinical features of the studied group with the NF1 p.Arg1809 and p.Met992del 439 
cohorts as well as previously described large-scale cohorts of individuals with “classic” NF1 is 440 
shown in Table 3. The complete list of adjusted p-values with FDRs at 0.05 and 0.01 after B-H 441 
correction for multiple testing is presented in Table S10. All p-values ≤0.0125 and p-values 442 
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≤0.0012 remained statistically significant after applying the B-H correction at FDRs of 0.05 and 443 
0.01, respectively. 444 
In the current study, we observed a significantly higher number of major external plexiform 445 
neurofibromas compared with the NF1 p.Arg1809 and the NF1 p.Met992del cohorts, as well as 446 
“classic” NF1 population (all p<0.0001; statistically significant after B-H correction at FDR of 447 
0.01). Importantly, while none of the individuals carrying the p.Arg1809 and p.Met992del had 448 
external plexiform, cutaneous and/or subcutaneous neurofibromas, ~71% of the individuals ≥19 449 
years with a missense mutation affecting codons 844-848 had cutaneous and/or subcutaneous 450 
neurofibromas (p<0.0001; statistically significant after B-H correction at FDR of 0.01) and 451 
~39% of the individuals ≥9 years had externally visible plexiform neurofibromas (p<0.0001; 452 
statistically significant after B-H correction at FDR of 0.01). Compared with p.Arg1809, 453 
p.Met992del and “classic” NF1 cohorts, at least 5-fold greater prevalence of symptomatic spinal 454 
neurofibromas was reported in the studied group (0-2.1% vs. 10.2%) which was statistically 455 
significant at FDR of 0.01 for the general NF1 population (p<0.0001) and at FDR of 0.05 for the 456 
p.Arg1809 cohort (p=0.0022). 457 
Symptomatic and asymptomatic OPGs were more frequent compared to individuals with 458 
p.Arg1809, p.Met992del and “classic” NF1, with symptomatic and asymptomatic OPGs 459 
statistically increased after B-H correction at FDR of 0.05 in the 844-848 cohort compared to the 460 
“classic” NF1 cohorts (p=0.0125 and p=0.0043, respectively) and at FDR of 0.01 compared with 461 
the p.Arg1809 cohort (p=0.0002 and p<0.0001, respectively). The overall prevalence of 462 
malignant neoplasms, other than neurofibromas and OPGs, was also higher in the studied group 463 
compared to a large cohort of “classic” NF1 individuals (9.4% vs. 3.4%; p=0.0061, statistically 464 
significant at FDR of 0.05 after B-H correction). 465 
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Additionally, the AA844-848 cohort had a significantly increased frequency of skeletal 466 
abnormalities compared to individuals with p.Arg1809 and “classic” NF1 phenotypes (both 467 
statistically significant after B-H correction at FDR of 0.05), regardless of the age. Scoliosis was 468 
reported more frequently compared with p.Arg1809 individuals (31.3% vs. 12.5% in ≥19 years), 469 
but this difference was not statistically significant after B-H correction. 470 
The prevalence of CALMs was lower than in p.Arg1809 and p.Met992del cohorts (both 471 
significant at FDR of 0.05 after B-H correction), while skinfold freckles occurred more common 472 
in “classic” NF1 cohorts than in the studied group (significant at FDR of 0.01 after B-H 473 
correction). Noonan syndrome features were significantly less frequent in the studied group 474 
compared to individuals with p.Arg1809 (significant at FDR of 0.01 after B-H correction). In 475 
line with this finding, pulmonic stenosis was very rarely observed in the cohort (1.8% vs. 10.6% 476 
in the p.Arg1809 cohort; significant at FDR of 0.05 after B-H correction). All cohorts, except for 477 
the p.Met992del, shared a similar frequency of cognitive impairment and/or learning difficulties 478 
(~45%).  479 
 480 
Discussion 481 
We present 162 individuals heterozygous for a constitutional NF1 missense mutation in one of 482 
five neighboring codons 844-848 who have a high prevalence of a severe NF1 phenotype, 483 
including plexiform and/or symptomatic spinal neurofibromas, symptomatic OPGs, other 484 
malignant neoplasms, as well as bone abnormalities. The frequency of the cluster of these 485 
mutations is ~0.8% (67/8400) in unrelated NF1 mutation-positive individuals from the UAB 486 
cohort, second only to the p.Arg1809 (~1.2%) among the missense variants.  487 
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One of the most severe complications in NF1 individuals are clinically apparent plexiform 488 
neurofibromas affecting 15-30% of the NF1 general population [8, 35, 47-50]. In this study, 489 
externally visible plexiform neurofibromas were found in ~39% of individuals ≥9 years, 490 
therefore significantly higher compared with p.Arg1809 and p.Met992del and “classic” NF1 491 
cohorts (significant at FDR of 0.01 after B-H correction; Table 3 and Table S10). Individuals in 492 
this study did not undergo whole body MRI; therefore the frequency provided here is a likely 493 
underestimate, as internal asymptomatic plexiform neurofibromas were not accounted for.  494 
As plexiform neurofibromas have been suggested to be associated with a higher lifetime risk for 495 
the development of MPNSTs [50-53], the finding of MPNSTs in 5% (7/139) of the affected in 496 
our cohort, which is twice as high as reported by Huson et al. (1989) in the South-East Wales 497 
cohort [29, 30], is in line with expectations.  498 
Approximately 24-40% of NF1 individuals develop spinal neurofibromas [36, 40, 52], but they 499 
are most often asymptomatic and not detectable by physical examination. The estimated 500 
prevalence of symptomatic spinal neurofibromas in the general NF1 population is less than 2% 501 
[8, 35, 36]. In the current study, a high number of individuals with symptomatic spinal 502 
neurofibromas was reported, compared to the “classic” NF1 cohorts (statistically significant at 503 
FDR of 0.01 after B-H correction): 13/127 (10.2%) for all ages and 12/79 (15.2%) for ≥ 9 years. 504 
Kluwe et al. (2003) [19] suggested that spinal neurofibromas cause symptoms mainly in older 505 
cases (mean age 32.8 years), but four of thirteen symptomatic individuals in our cohort were 506 
below age 18 (range: 7-17 years). In 40 individuals who underwent MRI examination, an 507 
additional seven cases with asymptomatic spinal neurofibromas were found. Among all affected 508 
individuals, five persons belonged to two previously reported multi-generation families (UG-509 
R923 and MAN-R95417G) where the spinal tumors segregated within the family [17, 22]. For 510 
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two relatives of these probands the spinal neurofibromas were only recognized after MRI, 511 
although the tumor burden was extensive. None of the individuals had >5 CALMs, including 2/5 512 
who had <6 CALMs and 3/5 had none. This rare form of NF1 is called “familial spinal 513 
neurofibromatosis” (FSNF).  514 
Plexiform and spinal tumors as well as subcutaneous neurofibromas are associated with a severe 515 
NF1 phenotype and may result in significant morbidity in children and adults [54, 55]. OPGs, the 516 
most common brain tumors in children, are another complication in the general NF1 population 517 
[56]. The overall prevalence of OPGs in the NF1 population is ~11-20% [40, 50, 57]; however, 518 
only ~30% of these individuals have clinically symptomatic OPGs and present with impaired 519 
visual acuity, visual field loss, abnormal color vision, squint, proptosis and/or hypothalamic 520 
dysfunction [49]. Most symptomatic OPGs are diagnosed before age 7 years [57] with the mean 521 
age of 5 years [58]. In the studied group, symptomatic OPGs were found in 11/104 (10.6%) of 522 
individuals ≥ 5 years, which is more frequent compared with p.Arg1809 and p.Met992del 523 
cohorts (none of the individuals had OPGs) and with “classic” NF1 population (3.9%); however, 524 
after applying the B-H correction only the result of comparison with p.Arg1809 cohort and the 525 
general NF1 population remained statistically significant at FDR of 0.05 (Table 3 and Table 526 
S10). Furthermore, there was a higher prevalence of asymptomatic OPGs in 16/52 (30.8%) 527 
individuals ≥5 years who underwent MRI examination (statistically significant at FDR of 0.01). 528 
Individuals with NF1 are at higher risk to develop specific malignancies compared with the 529 
general population, significantly increasing mortality [59, 60]. Besides the high-grade gliomas, 530 
the most common malignancies in NF1 children are rhabdomyosarcomas, JMML, and 531 
neuroblastomas, but accurate estimates on prevalence are not available due to the rarity of these 532 
tumors [61, 62]. Based on the data provided by Sung et al. (2004) [63] and Crucis et al. (2015) 533 
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[64], the prevalence of rhabdomyosarcomas in children with NF1 is estimated at 0.4-0.5%, while 534 
Chang and Shannon (2012) [65] reported that the individual risk of JMML in NF1 is ~0.04%. In 535 
the studied group, three NF1 children younger than 5 years developed embryonal 536 
rhabdomyosarcomas, including one individual, now >26 years, who survived both a 537 
rhabdomyosarcoma and astrocytoma grade II, diagnosed at the age two and 15 years, 538 
respectively. Furthermore, one five-year-old girl (out of 50 children ≤ 8 years) presented with <6 539 
CALMs and JMML. This girl was heterozygous for two pathogenic NF1 mutations in the blood, 540 
c.2542G>A (p.Gly848Arg), as well as c.1246C>T (p.Arg416*), with p.Gly848Arg being the first 541 
hit given the absence of p.Arg416* in buccal swabs, indicating somatic mosaicism for 542 
p.Arg416*. An UK population-based hospital admission and death certificate study found that 543 
individuals with NF1 have, after excluding the well-established risks of nervous systems tumors, 544 
a 2.7-fold increased risk of developing cancers of the esophagus, stomach, colon, liver, lung, 545 
bone, thyroid, malignant melanoma, non-Hodgkin lymphoma, chronic myeloid leukemia, breast 546 
and ovary [66]. In the current study, we noted recurrent malignant tumors, such as MPNSTs 547 
(7/139; 5%) (Table S1 and Table S8). Among these individuals, one 44-year-old woman 548 
previously described [67] with the missense mutation c.2540T>C (p.Leu847Pro) had MPNST, 549 
BRCA1/2-negative (MIM: 113705 and MIM: 600185) breast cancer as well as a high number of 550 
cutaneous neurofibromas (>100). In addition, one individual developed a medullary thyroid 551 
carcinoma and three first-degree relatives of a Belgian proband with c.2540T>C (p.Leu847Pro) 552 
died from malignancies (a metastasized colon adenocarcinoma and two MPNSTs, both deceased 553 
before age 26 year). Taken together, the overall prevalence of malignant neoplasms in the 554 
studied group was substantially higher than in the published datasets of the general NF1 555 
population (significant at FDR of 0.05 after B-H correction; Table 3 and Table S10). 556 
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Furthermore, specifically mutation p.Leu847Pro seems to confer a high predisposition to develop 557 
malignant tumors compared to other missense variants reported in this study (p<0.0448; Table 558 
S9), although the CADD score of this variant is not the highest among the studied region (only 559 
26.1). Given the predominance of the p.Leu847Pro mutations in the studied cohort (70/162 560 
individuals), larger datasets are required to further refine the increased tumor risk associated with 561 
the other mutations within the studied region. 562 
Skeletal abnormalities, including long bone dysplasia with or without pseudarthrosis, scoliosis, 563 
sphenoid wing dysplasia, bone cysts, including cherubism, non-ossifying fibromas and osseous 564 
giant cell lesions, hand anomalies, anterior chest wall anomalies and short stature, can lead to 565 
serious clinical consequences and significant morbidity [68]. We observed a clear overall 566 
increase in the number of skeletal anomalies compared with p.Arg1809 (FDR of 0.05 after B-H 567 
correction) and the general NF1 population (FDR of 0.01 after B-H correction). As many as 568 
33.3% of the NF1 individuals (48/144) presented with one or more osseous lesion, scoliosis 569 
(n=27) and pectus anomalies (n=10) being most frequent (18.8% and 6.9%, respectively). The 570 
overall frequency would be higher if individuals with short stature (40.3%; 58/144) are included. 571 
Rarely reported complications possibly associated with NF1 status included cherubism, chronic 572 
arthritis of multiple joints with elbow contractures, clinodactyly of the 3-5th toes, postaxial 573 
polydactyly and ulnar aplasia, likely representing the severe end of ulnar pseudarthrosis with 574 
bone resorption and absence of the ulnar bone. Interestingly, the latter has been reported only in 575 
two NF1 cases [69]. Mild to moderate scoliosis was reported in only 18% of NF1-positive 576 
individuals with bilateral neurofibromas of all spinal roots [18]; however, in our study we 577 
observed co-occurrence of scoliosis and spinal tumors in 45% (9/20) of individuals with 578 
confirmed symptomatic or asymptomatic spinal neurofibromas (not necessarily affecting all 579 
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dorsal roots) (Table S6). An additional 11 individuals had scoliosis without evidence of spinal 580 
neurofibromas by MRI (Table S1). 581 
Cohorts of individuals with NF1 missense mutations affecting codons 844-848 and “classic” 582 
NF1 population shared a similar frequency for short stature and macrocephaly. Noonan 583 
syndrome (NS) features were rarely observed in the studied group compared with the p.Arg1809 584 
cohort (significant at FDR of 0.01 after B-H correction). In line with previous studies [8, 35, 40, 585 
70], intellectual disability, developmental delay, and/or learning difficulties were frequently 586 
observed in the current study (40.6%).  587 
Among the 129 unrelated probands with a missense mutation affecting codons 844-848, 588 
p.Leu847Pro and p.Gly848Arg are the most recurrent variants, found in 58 and 14 unrelated 589 
individuals, respectively (Table S2 and Figure 1). Both alterations are associated with a severe 590 
NF1 phenotype, including a high prevalence of plexiform neurofibromas and skeletal 591 
abnormalities, compared to the general NF1 population. However, missense mutations at 592 
p.Gly848 predispose with a greater frequency to symptomatic or asymptomatic spinal tumors, 593 
which were found in ~70% of probands carrying the p.Gly848Arg or p.Gly848Glu mutations 594 
(9/13 ≥9 years, but in 9/10 ≥9 years who received MRI screening), that is slightly higher than in 595 
individuals presenting with a severe phenotype caused by a total NF1 deletion (8/13 ≥9 years) 596 
[71]. Several of the severely affected individuals with a missense mutation at p.Gly848 had only 597 
few or no pigmentary skin findings. So far, ~100 cases have been reported with the true “spinal 598 
NF” phenotype [18] and these individuals more frequently carry a splice site or missense 599 
mutation spread over the entire NF1 coding region. So far, no single mutation has been 600 
correlated with this severe clinical presentation. We provide the specific genotype-phenotype 601 
association between a particular NF1 mutation and the spinal phenotype. Individuals with 602 
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missense mutations at p.Gly848 appear to constitute a distinct group of NF1 individuals with a 603 
high prevalence of symptomatic spinal neurofibromas and a clear decrease of pigmentary 604 
manifestations (CALMs and skinfold freckles) as well as cutaneous neurofibromas (Table 2 and 605 
Table S9). Because of the limited number of individuals ≥9 years old with the missense 606 
mutations at codons 844-846, it is still difficult to establish a genotype-phenotype correlation 607 
among these cohorts; however, so far these variants also seem to be associated with a severe 608 
phenotype, including a high prevalence of plexiform neurofibromas in the p.Cys845 and 609 
p.Ala846 cohorts (57.1% and 66.7%, respectively) and OPGs in p.Leu844 cohort (~24% for both 610 
symptomatic and asymptomatic OPGs in ≥5 years). At this moment, it cannot be excluded that 611 
two specific genotype-phenotype correlations exist within this small region of NF1 with the NF1 612 
codon 847 associated with an increased risk for malignant neoplasia and the NF1 codon 848 613 
associated with a high prevalence of symptomatic spinal neurofibromas. The current study, 614 
however, intended to show that the whole region of 844-848 codons stood out due to its high 615 
frequency of variants compared with the neighboring codons, indicating functional importance. 616 
In addition, the cluster of missense mutations here described, although located outside the GRD 617 
important for RAS-regulation, is clearly associated with a severe phenotype, not reported so far 618 
in literature. As the current study necessarily still underestimates the internal tumor burden, as 619 
systematic whole body imaging was not performed, close clinical management seems warranted 620 
for individuals presenting with a missense variant affecting the AA844-848. 621 
As NF1 is known for its variable expressivity and age-dependency, it is challenging to establish 622 
genotype-phenotype correlations. Although we performed a comparative analysis on a large 623 
well-described cohort using a standardized phenotypic data collection form, one limitation of the 624 
study is that clinical information was collected by physicians from different referral centers, 625 
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although all were NF1 specialists. Data in this and the previously reported p.Arg1809 cohort 626 
were “double-checked” through verification of the originally submitted phenotypic checklist 627 
forms and subsequent update of the clinical notes, so data should be highly accurate.  628 
Clinical variability, both inter- and intrafamilial, has been widely reported in the past two 629 
decades [72-74]. Although significant progress has been made over the last twenty years, the 630 
mechanisms underlying this phenotypic heterogeneity only gradually start to be unraveled. The 631 
factors contributing to the phenotypic variability include: i/ age-dependency of some of the NF1 632 
features [30, 75, 76]; ii/ timing, cell-of-origin and number of second hits in specific cells, 633 
resulting in presence and number of CALMs, freckling, tibial dysplasia, neurofibromas and other 634 
tumors [77]; iii/ post-zygotic mosaicism for the first NF1 hit in mosaic individuals [77]; iv/ the 635 
enormous NF1 allelic heterogeneity [78]; v/ occasional presence of two different NF1 pathogenic 636 
variants segregating within a family (see MAD-R9.232; Table S1 and Figure S5) or the 637 
occurrence of two independent mutations (one in NF1 and the other in a different gene) within an 638 
individual (see UAB-R624 with the NF1/PTPN11 mutations and UF-R1 with the NF1/KIT 639 
mutations; Table S1); vi/ modifying genes [79] and vii/ environmental factors (e.g. number of 640 
pregnancies) [80]. To date, two studies have identified potential modifying genes, unlinked to the 641 
NF1 locus, associated with the severity of NF1 presentation [81, 82]. Pasmant et al. (2011) 642 
demonstrated that a high number of plexiform neurofibromas has been significantly associated 643 
with allele T of SNP rs2151280 of ANRIL (MIM: 613149) [81]. Pemov et al. (2014) reported a 644 
correlation of two common SNPs (rs4660761 and rs7161), located between DPH2 (MIM: 645 
603456) and ATP6V0B (MIM: 603717), as well as of SNP rs1800934 in MSH6 (MIM: 600678) 646 
with the number of CALMs [82]. Further studies are needed to confirm these findings. 647 
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Missense mutations affecting NF1 codons 844-848 described in this study are clearly pathogenic 648 
and individuals with these missense mutations have a statistically higher risk of developing 649 
spinal neurofibromas, plexiform neurofibromas and OPGs. Functional studies in mutant mice 650 
harboring the missense mutation c.2542G>C (p.Gly848Arg), however, did not recapitulate this 651 
human phenotype, as neither optic pathway gliomas [24] nor plexiform neurofibromas [23] 652 
developed. Western blot analysis showed that c.2542G>C (p.Gly848Arg) resulted in 38-50% 653 
reduction of neurofibromin levels [23, 24]. These mutations reside outside the GRD (amino acids 654 
1203-1549), known to have tumor-suppressor activity through downregulation of members of the 655 
Ras family of small GTP-binding proteins. Although NF1 was cloned in 1990, the cellular 656 
functions performed by this huge 2818-amino acid multi-domain protein are still incompletely 657 
understood. The cluster of recurrent missense mutations involving AA844-848 described in the 658 
current study are located within the CSRD (amino acids 543-909), located N-terminal to the 659 
GRD. The CSRD domain, originally described by Fahsold et al (2000) [83], is likely functionally 660 
important, which is further implied by the presence of multiple missense variants in this segment 661 
of the gene in NF1 individuals. The 3D structure of this region has not been resolved and its 662 
precise functions and interactors have not been described. Ras GAP activity is enhanced through 663 
phosphorylation by Protein Kinase Cα of serine and threonine residues within this domain [84]. 664 
Based on the 2D-modeling of the CSRD using PredictProtein server [85], the region 831-847 665 
might form the C-part of a helix and be buried in the protein. Missense mutations affecting 666 
codons 844-848, especially those substituting smaller hydrophobic amino acids to large ones, 667 
may result in breaking of the helix and exposure of the buried protein domain, consequently 668 
affecting the function of the protein. No functional studies confirming the aforementioned 669 
bioinformatics analysis have been performed, however. In any case, missense mutations in this 670 
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region seem to act through a loss-of-function mechanism and not gain-of-function or dominant-671 
negative, at least in melanocytes and JMML. Indeed, the c.2540T>C (p.Leu847Pro) was 672 
observed as a “second hit” in one CALM, biopsied from a 13.5-year-old girl with >5 CALMs 673 
and skinfold freckling carrying the NF1 constitutional mutation c.5547-1G>A (Table S11), 674 
confirming that two hits are required to cause a phenotypic effect. Additionally, we reported a 675 
five-year-old girl with JMML (UAB-R9493; Table S1) who carried two pathogenic NF1 676 
mutations in the blood: c.2542G>A (p.Gly848Arg) as a “first hit” mutation and c.1246C>T 677 
(p.Arg416*) as a “second hit”. There is a need to improve our understanding of the physiological 678 
functions of neurofibromin and to determine how each domain regulates the function of this 679 
protein.  680 
Six amino acids in the region AA804-950 are evolutionarily conserved down to yeast (IRA1 and 681 
IRA2), Leu844, Gly849, Leu852, Glu923, Leu933 and Phe934 (Figure S6), and would therefore 682 
be expected to be of particular functional importance [86]. Only Leu844 and Leu933 have 683 
however been observed in NF1 individuals to predispose to recurrent missense mutations 684 
(HGMD, LOVD, ClinVar and our cohort). The tumorigenic potential of AA844 is further 685 
highlighted by identification of somatic mutations in the COSMIC database: one glioma with 686 
p.Leu844Pro, one glioma and four malignant melanomas with p.Leu844Phe. 687 
Palindromic structures belong to the non-B DNA-structures and are often the site of replication 688 
errors resulting in substitutions [87]. The NF1 missense mutation hotspot (AA844-848) is 689 
located in the highly conserved amino acid region, suggesting it is functionally important. The 690 
genomic sequence encoding the human NF1 AA845-853 is a part of two palindromic structures 691 
(Figure S7); therefore the high rate of recurrent missense mutations affecting Leu847 and 692 
Gly848 may partially be due these being both located in the loop of the palindrome. In NF1 exon 693 
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21 [16] other palindromic nucleotide sequences, specifying the amino acid residues AA828-832, 694 
AA865-868, AA908-911 and AA933-937 are observed, resulting in four additional stem-loop 695 
structures. However, these structures do not predispose to recurrent missense mutations as none 696 
were found either in the UAB, HGMD or LOVD cohort, except for c.2798T>C (p.Leu933Pro), 697 
whose location does not include the loop of the palindrome. The complex interplay between 698 
functional significance and genomic architecture needs to be considered when analyzing the 699 
recurrence of mutations.  700 
Although only few clear genotype-phenotype correlations have been so far reported [12-15], the 701 
data here presented show that additional clinically relevant NF1 genotype-phenotype correlations 702 
exist. A renewed interest in such studies is needed to come to a timely unfolding of additional 703 
correlations, as so far only the surface has been scratched. This will require close collaboration 704 
between NF1 clinicians and molecular geneticists. The lack of discovery of more specific 705 
genotype-phenotype correlations may be partly due to the methodological approach, including 706 
lumping mutations in large categories (truncating versus microdeletion, splice, missense 707 
mutations) [88, 89]. Identification of mutation-specific genotype-phenotype correlations depends 708 
on the datasets size with a large number of individuals, preferentially postpubertal, carrying the 709 
same non-truncating constitutional mutation, with the associated phenotype recorded in a 710 
standardized way. As there are only a limited number of truly recurrent non-truncating 711 
mutations, prioritization on individuals carrying such recurrent mutations is indicated. Although 712 
each of the recurrent mutation affects only a small percentage of NF1 individuals (3-8% with the 713 
microdeletion type I, ~0.8% with p.Met992del, ~1.2% with the p.Arg1809 missense mutation 714 
and ~0.8% for the cluster of missense mutations affecting codons 844-848), together they may 715 
affect counseling and surveillance in a significant fraction of the NF1 population. 716 
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In conclusion, the present findings indicate that missense mutations affecting one of five 717 
neighboring codons 844-848 located outside the GAP-related domain are an important risk factor 718 
for a severe phenotype in NF1 individuals. We report that these individuals have a high 719 
prevalence of plexiform and/or spinal neurofibromas, symptomatic and asymptomatic OPGs, 720 
malignant neoplasms and skeletal abnormalities. A severe phenotype was observed in 75% of 721 
adult NF1 individuals with these mutations, clearly demonstrating that missense mutations 722 
outside the GRD can be associated with a severe clinical presentation. The current study 723 
identified a genotype-phenotype correlation in this region that may be valuable in the 724 
management and genetic counseling of a significant number of NF1 individuals. These data 725 
suggest there is a potential need for increased disease surveillance in individuals with these 726 
mutations enabling genotype driven personalized medicine.  727 
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Table 1. Demographic and clinical characterization of the individuals with a missense mutation affecting codons 844-848. 
A All bone abnormalities included, that is, scoliosis (n=27), pectus excavatum (n=4), pectus carinatum (n=6), long bone dysplasia (n=4), pseudarthrosis (n=2), bone cysts (n=2), sphenoid wing dysplasia (n=2), ulnar aplasia, dural ectasia, 4th lumbar vertebrae fragmentation, bowed long 
bones, tibial dysplasia, clinodactyly, postaxial polydactyly and cherubism. B At least two cutaneous/subcutaneous neurofibromas were required to be considered as “positive for the criterion of neurofibromas”. C The frequency of both symptomatic and asymptomatic spinal 
 Codon 844 Codon 845 Codon 846 Codon 847 Codon 848 All codons 844-848 Total 
Mutation 
[Proband:Relative] 
c.2530C>T (p.Leu844Phe) [10:1] 
c.2531T>A (p.Leu844His) [2:0] 
c.2531T>C (p.Leu844Pro) [7:0] 
c.2531T>G (p.Leu844Arg) [6:0] 
c.2533T>C (p.Cys845Arg) [3:1] 
c.2534G>A (p.Cys845Tyr) [8:0] 
c.2536G>C (p.Ala846Pro) [1:2] 
c.2537C>A (p.Ala846Asp) [5:2] 
c.2540T>C (p.Leu847Pro) [58:12] 
c.2540T>G (p.Leu847Arg) [8:0] 
c.2542G>A (p.Gly848Arg) [6:0] 
c.2542G>C (p.Gly848Arg) [8:11] 
c.2543G>A (p.Gly848Glu) [7:4] 
  
Mutation positive individuals 
[Proband:Relative] 
26 
[25:1] 
12 
[11:1] 
10 
[6:4] 
78 
[66:12] 
36 
[21:15] 
162 
[129:33] 
 
Age group, years 
Total 
Proband:Relative 
Age range, years 
≤8 
12 
12:0 
1-8 
9-18 
5 
5:0 
9-16 
≥19 
9 
8:1 
24-55 
≤8 
4 
4:0 
1-2 
9-18 
2 
2:0 
15-16 
≥19 
6 
5:1 
19-48 
≤8 
3 
2:1 
4-5 
9-18 
1 
1:0 
18 
≥19 
6 
3:3 
33-69 
≤8 
28 
27:1 
1-8 
9-18 
14 
12:2 
9-18 
≥19 
36 
27:9 
19-72 
≤8 
13 
6:7 
1-7 
9-18 
5 
4:1 
10-17 
≥19 
18 
11:7 
19-74 
≤8 
60 
51:9 
1-8 
9-18 
27 
24:3 
9-18 
≥19 
75 
54:21 
19-74 
All ages 
162 
129:33 
1-74 
Male: Female 6:6 4:1 1:8 1:3 1:1 1:5 2:1 0:1 1:5 10:18 5:9 19:17 9:4 2:3 5:13 28:32 12:15 27:48 67:95 
Fulfilling the NIH criteria  
if the family history is taken 
into account 
10/11 4/5 9/9 2/4 1/2 4/5 3/3 1/1 6/6 17/28 14/14 35/36 4/11 4/5 17/18 36/57 24/27 71/74 131/158 
Fulfilling the NIH criteria 
 if solely taking the physical 
signs into account 
10/11 4/5 9/9 2/4 1/2 4/5 2/3 1/1 6/6 17/28 14/14 33/36 4/11 4/5 13/18 35/57 24/27 65/74 124/158 
> 5 CALMs 
Freckling 
Lisch nodules 
Skeletal abnormalities A 
12/12 
10/10 
2/9 
2/11 
5/5 
4/5 
1/4 
2/5 
8/8 
6/7 
4/4 
5/9 
4/4 
0/4 
0/1 
2/4 
1/2 
1/2 
0/0 
1/2 
4/5 
4/5 
1/2 
2/4 
3/3 
2/2 
0/1 
0/2 
1/1 
1/1 
0/1 
0/1 
4/6 
5/5 
2/2 
0/5 
27/28 
12/23 
4/19 
3/25 
14/14 
13/13 
3/9 
3/14 
32/35 
31/34 
17/19 
17/28 
5/11 
4/10 
2/8 
3/11 
3/5 
3/5 
0/5 
3/5 
7/18 
8/18 
6/14 
5/18 
51/58 
28/49 
8/38 
10/53 
24/27 
22/26 
4/19 
9/27 
55/72 
54/69 
30/41 
29/64 
130/157 
104/144 
42/98 
48/144 
Plexiform neurofibromas 
Cutaneous neurofibromas B 
Subcutaneous neurofibromas B 
Cutaneous and subcutaneous B 
Symptomatic spinal NF 
Spinal neurofibromas by MRI C 
0/11 
1/11 
1/9 
0/9 
0/10 
0/1 
2/5 
1/5 
0/5 
0/5 
0/3 
0/0 
3/9 
7/9 
6/8 
5/8 
0/8 
0/5 
0/3 
0/4 
1/4 
0/4 
0/2 
0/0 
2/2 
0/2 
0/2 
0/2 
1/2 
1/2 
2/5 
3/4 
1/4 
1/3 
0/4 
1/1 
0/2 
0/2 
0/2 
0/2 
0/2 
0/1 
1/1 
1/1 
0/0 
0/0 
0/0 
0/0 
1/2 
4/5 
3/5 
3/5 
0/2 
0/1 
6/24 
1/26 
1/26 
0/25 
1/23 
1/5 
3/13 
4/14 
4/13 
1/13 
1/13 
2/6 
19/33 
28/33 
17/30 
17/30 
2/27 
3/16 
0/11 
1/11 
1/11 
0/11 
0/11 
0/1 
1/5 
1/5 
0/5 
0/5 
1/4 
2/3 
7/17 
5/18 
6/18 
4/18 
7/16 
10/11 
6/51 
3/54 
4/52 
0/51 
1/48 
1/8 
9/26 
7/27 
4/25 
1/25 
3/22 
5/11 
32/66 
47/69 
33/65 
30/64 
9/57 
14/34 
47/143 
57/150 
41/142 
31/140 
13/127 
20/53 
Symptomatic OPGs D 
Asymptomatic OPGs E 
Other neoplasms F 
1/11 
2/6 
1/11 
1/5 
1/2 
0/4 
0/9 
2/4 
1/8 
0/3 
0/1 
0/2 
0/2 
0/2 
0/1 
0/5 
0/2 
0/4 
1/3 
0/1 
0/2 
1/1 
0/0 
0/1 
0/3 
0/3 
0/3 
2/25 
1/8 
1/24 
1/13 
6/9 
3/14 
2/27 
4/13 
11/34 
1/11 
1/4 
2/11 
1/5 
0/2 
1/5 
1/13 
1/6 
1/15 
5/53 
4/20 
4/50 
4/26 
7/15 
4/25 
3/57 
7/28 
13/64 
12/136 
18/63 
21/139 
Cognitive impairment 
and/or learning disabilities 
3/11 3/4 0/6 1/4 0/2 3/4 3/3 0/1 1/5 10/26 7/13 12/26 5/11 5/5 3/17 22/55 15/25 19/58 56/138 
Noonan syndrome features 
Short stature G 
Macrocephaly 
Pulmonic stenosis 
0/9 
1/7 
2/11 
0/8 
1/5 
0/2 
1/4 
1/5 
1/8 
0/4 
1/2 
0/6 
0/2 
0/3 
1/3 
0/2 
1/1 
1/1 
0/1 
0/2 
0/4 
0/1 
0/0 
1/1 
0/2 
0/2 
2/2 
0/3 
0/1 
0/0 
0/0 
0/0 
0/4 
1/2 
0/2 
0/5 
3/27 
0/11 
8/21 
0/23 
0/13 
3/10 
2/11 
0/13 
3/26 
4/21 
10/17 
0/20 
1/10 
3/10 
3/11 
0/8 
0/5 
0/3 
1/4 
0/3 
0/17 
2/14 
5/9 
0/14 
4/50 
4/33 
16/48 
0/44 
2/25 
4/16 
4/20 
1/23 
4/59 
7/42 
16/30 
1/46 
10/134 
15/91 
36/98 
2/113 
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neurofibromas in individuals who had done MRI examination. D The presence or absence of symptomatic OPGs was determined by ophthalmological examination and confirmed by MRI. E Including only individuals without signs of symptomatic OPGs who underwent MRI 
examination. F Including benign and malignant neoplasms, except for OPGs and neurofibromas. GAs no specific growth curves are available for the Hispanic and Asian populations, Hispanic and Asian individuals were excluded as having short or normal stature. 
Table 2. Frequency of clinical features in cohorts of individuals with a missense mutation affecting Leu844, Cys845, Ala846, Leu847 and Gly848. 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 
 
A In individuals ≥9 years. B In individuals ≥19 years. C The frequency of both symptomatic and asymptomatic spinal neurofibromas in individuals who had done MRI examination. D The presence or absence of symptomatic 
OPGs was determined by ophthalmological examination and confirmed by MRI. E Including only individuals without signs of symptomatic OPGs who underwent MRI examination. F Including benign and malignant 
neoplasms, except for OPG and neurofibromas. G As no specific growth curves are available for the Hispanic and Asian populations, Hispanic and Asian individuals were excluded as having short or normal stature. H 
Individual was classified as having a severe phenotype if at least one of the following features was observed: plexiform and/or symptomatic spinal neurofibroma, symptomatic OPG, malignant neoplasm or osseous lesions. I 
Among individuals with a missense mutation affecting codon 846, the status of plexiform and spinal neurofibromas was known only for 2/6 individuals (UG-R0781-S and UG-R665-F), thus a severe phenotype cannot be 
excluded in the remaining four individuals with missing data.  
NF1 feature 
Number of individuals (%) [95% Confidence Interval] 
 
Leu844  Cys845 Ala846 Leu847 Gly848  
>5 CALMs 25/25 (100) [86.7-100] 9/11 (81.8) [52.3-94.9] 8/10 (80) [49-94.3] 73/77 (94.8) [87.4-98] 15/34 (44.1) [28.9-60.6]  
Skinfold freckling A 10/12 (83.3) [55.2-95.3] 5/7 (71.4) [35.9-91.8] 6/6 (100) [61-100] 44/47 (93.6) [82.8-97.8] 11/23 (47.8) [29.2-67] 
Lisch nodules 7/17 (41.2) [21.6-64] 1/3 (33.3) [6.2-79.2] 2/4 (50) [15-85] 24/47 (51.1) [37.2-64.7] 8/27 (29.6) [15.9-48.5] 
Plexiform neurofibromas A 5/14 (35.7) [16.3-61.2] 4/7 (57.1) [25-84.2] 2/3 (66.7) [20.8-93.9] 22/46 (47.8) [34.1-61.9] 8/22 (36.4) [19.7-57] 
Cutaneous neurofibromas B 7/9 (77.8) [45.3-93.7] 3/4 (75) [30.1-95.4] 4/5 (80) [37.6-96.4] 28/33 (84.9) [69.1-93.4] 5/18 (27.8) [12.5-50.9] 
Subcutaneous neurofibromas B 6/8 (75) [40.9-92.9] 1/4 (25) [4.6-69.9] 3/5 (60) [23.1-88.2] 17/30 (56.7) [39.2-72.6] 6/18 (33.3) [16.3-56.3] 
Symptomatic spinal neurofibromas A 0/11 (0) [0-25.9] 1/6 (16.7) [3-56.4] 0/2 (0) [0-65.8] 3/40 (7.5) [2.6-19.9] 8/20 (40) [21.9-61.3] 
Spinal neurofibromas by MRI  A, C 0/5 (0) [0-43.5] 2/3 (66.7) [20.8-93.9] 0/1 (0) [0-79.4] 5/22 (22.7) [10.1-43.4] 12/14 (85.7) [60.1-96] 
Symptomatic OPGs, age ≥5 years D 1/21 (4.8) [0.9-22.7] 0/7 (0) [0-35.4] 2/5 (40) [11.8-76.9] 5/47 (10.6) [4.6-22.6] 3/24 (12.5) [4.3-31] 
Asymptomatic OPGs, age ≥5 years E 
Other neoplasms F 
4/10 (40) [16.8-68.7] 
2/23 (8.7) [2.4-26.8] 
0/4 (0) [0-49] 
0/7 (0) [0-35.4] 
0/3 (0) [0-56.2] 
0/6 (0) [0-39] 
11/25 (44) [26.7-62.9] 
15/72 (20.8) [13.1-31.6] 
1/10 (10) [1.8-40.4] 
4/31 (12.9) [5.1-28.9] 
Bone abnormalities  9/25 (36) [20.3-55.5] 5/10 (50) [23.7-76.3] 0/8 (0) [0-32.4] 23/67 (34.3) [24.1-46.3] 11/34 (32.4) [19.1-49.2] 
Noonan syndrome features 2/22 (9.1) [2.5-27.8] 1/7 (14.3) [2.6-51.3] 0/7 (0) [0-35.4] 6/66 (9.1) [4.2-18.5] 1/32 (3.1) [0.6-15.8] 
Pulmonic stenosis 1/19 (5.3) [0.9-24.6] 1/5 (20) [3.6-62.5] 0/8 (0) [0-32.4] 0/56 (0) [0-6.4] 0/25 (0) [0-13.3] 
Short stature G 1/13 (7.7) [13.7-33.3] 1/5 (20) [3.6-62.5]  1/4 (25) [4.6-69.9] 7/42 (16.7) [8.3-30.6] 5/27 (18.5) [8.2-36.7] 
Macrocephaly 4/17 (23.5) [9.6-47.3] 1/4 (25) [4.6-69.9] 2/4 (50) [15-85] 20/49 (40.8) [28.2-54.8] 9/24 (37.5) [21.2-57.3] 
Cognitive impairment  
and/or learning disabilities 
6/21 (28.6) [13.8-50] 4/10 (40) [16.8-68.7] 4/9 (44.4) [18.9-73.3] 29/65 (44.6) [33.2-56.7] 13/33 (39.4) [24.7-56.3] 
Severe phenotype, age ≥19 years H 7/9 (77.8) [45.3-93.7] 4/6 (66.7) [30-90.3] 1/6 (16.7) [3-56.4] I 32/36 (88.9) [74.7-95.6] 12/18 (66.7) [43.8-83.7]  
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Table 3. Comparison of clinical features of the studied group with the NF1 Arg1809 cohort, the NF1 Met992del cohort and large-scale cohorts of individuals with “classic” NF1. 
 
*All bold and underlined p-values represent statistically significant p-values with false discovery rates of 0.05 (only bold p-values) and 0.01 (bold and underlined p-values), respectively after correction for multiple testing using Benjamini-Hochberg 
procedure (see details in Table S10). After applying the Benjamini-Hochberg correction p-values ≤0.0125 remained statistically significant at FDR of 0.05, while p-values ≤0.0012 were still be considered as significantly different at FDR of 0.01. The black 
arrows indicate the statistically significant differences of the NF1 clinical features prevalence between the studied group and the cohort(s) used for the comparison with the up and down arrows representing an increase and a decrease of the prevalence in the 
studied group, respectively. 
NF1 feature 
Number of individuals (%)  p value (2-tailed Fisher’s exact test) * 
AA844-848  Arg1809 A Met992del B Previous NF1 cohorts C  
AA844-848 
vs. Arg1809 
AA844-848  
vs. Met992del 
AA844-848  
vs. “classic” NF1 
           
>5 CALMs 130/157 (82.8) 157/169 (92.9) 46/47 (97.9) 1537/1728 (89) e 
 
0.0060 ↘ 0.0067 ↘ 0.0263 ↘ 
Skinfold freckling 104/144 (72.2) 95/161 (59) 32/47 (68.1) 1403/1667 (84.2) e 0.0164 ↗  0.0007 ↘ 
Lisch nodules 42/98 (42.9) 12/120 (10) 3/38 (7.9)  729/1237 (58.9) e <0.0001 ↗ <0.0001 ↗ 0.0028 ↘ 
Major external plexiform 
neurofibromas D 
36/92 (39.1) 0/105 (0) 0/41 (0) 120/648 (18.5) a,g <0.0001 ↗ <0.0001 ↗ <0.0001 ↗ 
Cutaneous neurofibromas E 47/69 (68.1) 0/57 (0) 0/18 (0) 656/723 (90.7) b,g,k,l <0.0001 ↗ <0.0001 ↗ <0.0001 ↘ 
Subcutaneous neurofibromas E 33/65 (50.8) 0-5/57 (0-8.8) I ND 297/515 (57.7) g,k,l <0.0001  ↗    
Symptomatic spinal neurofibromas D, F 
12/79 (15.2) 
 13/127 (10.2) 
0/40 (0) 
0/76 (0) 
1/41 (2.4) 
1/47 (2.1) 
2/119 (1.7) a 
36/2058 (1.8) a,g,h  
0.0080 ↗  
0.0022 ↗ 
0.0341 ↗ 
 
0.0004 ↗ 
<0.0001 ↗ 
Symptomatic OPGs, age ≥5 years F, G 
11/104 (10.6) 
12/136 (8.8) 
0/114 (0)  
0/139 (0) 
0/46 (0)  
0/47 (0) 
7/180 (3.9) a,d  
64/1650 (3.9) e 
0.0002 ↗  
0.0002 ↗ 
0.0186 ↗ 
0.0384 ↗ 
 0.0404 ↗ 
0.0125 ↗ 
Asymptomatic OPGs, age ≥5 years F, H 
16/52 (30.8)  
18/63 (28.6) 
0/35 (0)  
0/38 (0) 
ND 
2/45 (4.4) d  
70/519 (13.5) c,j,m 
0.0001 ↗  
<0.0001 ↗ 
 
0.0012 ↗  
0.0043 ↗ 
Other malignant neoplasms J 13/139 (9.4) 2/155 (1.3) K 0/47 (0) 18/523 (3.4) g 0.0023 ↗ 0.0409 ↗ 0.0061 ↗ 
Bone abnormalities D, F 
38/91 (41.8)  
48/144 (33.3) 
14/72 (19.4)  
21/126 (16.7) 
8/41 (19.5)  
9/47 (19.2) 
14/96 (14.6) a   
144/948 (15.2)  a,f,g,l 
0.0025 ↗  
0.0020 ↗ 
0.0174 ↗  
 
<0.0001 ↗ 
<0.0001 ↗ 
Scoliosis E 20/64 (31.3) 6/48 (12.5) 2/18 (11.1) 51/236 (21.6) b,l 0.0241 ↗   
Noonan syndrome features 10/134 (7.5) 46/148 (31.1) 4 (all from 1 family) 57/1683 (3.4) e <0.0001 ↘  0.0276 ↗ 
Pulmonic stenosis 2/113 (1.8) 14/132 (10.6) 4/47 (8.5) 25/2322 (1.1)  i 0.0076 ↘   
Short stature 15/91 (16.5) 32/111 (28.8) 5/47 (10.6) 109/684 (15.9)  a,k 0.0451 ↘   
Macrocephaly 36/98 (36.7) 31/107 (29) 4/45 (8.9) 239/704 (33.9)  a,k  0.0005 ↗  
Cognitive impairment  
and/or learning disabilities 
56/138 (40.6) 80/159 (50.3) 8/47 (17) 190/424 (44.8)  a,g  0.0042 ↗   
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A Based on data from Nyström et al. (2009) [26], Ekvall et al. (2014) [27], Pinna et al. (2015) [14], Rojnueangnit et al. (2015) [15] and Santoro et al. (2015) [28]. B Based on data from Upadhyaya et al. (2007) [13]. C Previous NF1 cohorts used for 
comparison: a/ Huson et al. (1988) [8]; b/ Huson et al. (1989a) [29] and Huson et al. (1989b) [30]; c/ Listernick et al. (1994) [31]; d/ Van Es et al. (1996) [32]; e/ Friedman and Birch (1997) [33]; f/ Cnossen et al. (1998) [34]; g/ McGaughran et al. (1999) 
[35]; h/ Thakkar et al. (1999) [36]; i/ Lin et al. (2000) [37]; j/ Blazo et al. (2004) [38]; k/ Khosrotehrani et al. (2005) [39]; l/ Plotkin et al. (2012) [40]; m/ Blanchard et al. (2016) [41]. D In individuals ≥9 years in this study and Arg1809, ≥10 years in 
Met992del and other studies. E In individuals ≥19 years in this study and Arg1809, ≥20 years in Met992del and other studies. F Second value is the frequency of a particular feature regardless of the individuals’ age. G The presence or absence of 
symptomatic OPGs was determined by ophthalmological examination and confirmed by MRI. H Including only individuals without signs of symptomatic OPGs who underwent MRI examination. I Five individuals with few (1-6) small, subcutaneous 
“possible” neurofibromas, none were biopsied and therefore none have been histologically confirmed (Rojnueangnit et al., 2015) [15]. J Only malignant neoplasms, hence excluding neurofibromas and OPGs, have been taken into account. K Breast cancer 
(n=1) and Ewing sarcoma (n=1) were found in the NF1 Arg1809 cohort (Rojnueangnit et al., 2015) [15]; no follow-up information on these individuals was available. ND: no data. 
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Figure 1. Spectrum of missense mutations affecting NF1 codons 844-848 in the cohort of 129 probands (A) and 
33 relatives (B).  
Each number in circle corresponds with the total number of individuals heterozygous for a specific mutation. The black dotted lines on 
the panels present the regions 844-848. The figure was prepared using the ProteinPaint application [90].
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